世界の3Dプリンティング医療機器市場は、予測期間中に約18%のCAGRで推移し、2021年から2025年の間に23億9,000万USドルの成長が見込まれています。本レポートは、総体的な分析、市場規模と予測、動向、成長推進要因、課題、および約25のベンダーを対象とするベンダー分析を提供しています。
本レポートは、現在の世界市場シナリオ、最新動向と成長推進要因、および全体的な市場環境に関する最新の分析を提供します。同市場は、パーソナライズまたはカスタマイズされた医療機器に対する需要の増加と、医療専門家による3Dプリンティング技術の採用増加によって促進されています。さらに、パーソナライズまたはカスタマイズされた医療機器に対する需要の増加は、市場の成長も後押しすると予想されます。
Technavio社の堅牢なベンダー分析は、クライアントが市場での地位を向上させるのに役立つように設計されており、これに沿って、主要な3Dプリンティング医療機器市場ベンダーの詳細な分析を提供します
この調査は、業界の主要な参加者からの情報を含む、一次情報と二次情報の客観的な組み合わせを使用して実施されました。本レポートには、主要ベンダーの分析に加えて、包括的な市場とベンダー情勢が含まれています。
Technavio社は、利益、価格設定、競争、プロモーションなどの主要なパラメーターの分析により、複数のソースからのデータの調査、統合、および集計により、市場の詳細な状況を提示します。また、業界の主要なインフルエンサーを特定することにより、さまざまな市場の側面を提示します。提示されたデータは、包括的で信頼性が高く、一次および二次の広範な調査の結果です。Technavio社の市場調査レポートは、完全な競争環境と、質的および量的調査を使用して正確な市場成長を予測する詳細なベンダー選択の調査手法と分析を提供します。
目次
Table of Contents
1 Study Design
1.1 Respondent Mix
1.2 Objectives and Design
1.3 Brexit Timeline
1.4 Respondent Profiles
2 Executive Summary
2.1 Executive Summary
3 UK Pharma Industry and Brexit
3.1 The UK - Real GDP Growth
3.2 The UK Pharma Industry
3.3 Clinical Trial Disruption COVID-19 - A Closer Look
3.4 Change in Brexit Sentiment
3.5 Change in Brexit Sentiment - Respondents’ Perspective
3.6 Brexit and COVID-19 Impact on the UK’s Healthcare Sector
3.7 Emerging Regulatory and Macroeconomic Trends
4 Outcome of Brexit
4.1 The UK-EU Trade and Cooperation Agreement
4.2 Best Outcomes of Brexit
4.3 Best Outcomes of Brexit by Geography
4.4 Best Outcomes of Brexit - Historical Data
4.5 Respondents’ Views on Brexit
5 Impact on Research and Manufacturing
5.1 Brexit’s Impact on Research and Manufacturing
5.2 The UK Pharma Industry Post Brexit
5.3 The UK Pharma Industry Post Brexit - Positives
5.4 The UK Pharma Industry Post Brexit - Negatives
6 Factors to Impact Healthcare
6.1 Factors to Impact the UK’s Healthcare Industry Post Brexit
6.2 Factors to Impact the UK’s Healthcare Industry Post Brexit - Historical Data
6.3 Factors to Impact the UK’s Healthcare Industry Post Brexit by Geography
6.4 The UK-EU Trade and Cooperation Agreement
6.5 Horizon Europe 2020
6.6 The UK-EU Trade and Cooperation Agreement
7 Impact on Corporate Strategy
7.1 Brexit’s Impact on Corporate Strategy
7.2 Brexit’s Impact on Corporate Strategy - 2018 and 2019 Data
7.3 How Has Brexit Most Influenced Corporate Strategy?
7.4 The UK’s Immigration Policy Post Brexit
7.5 UK’s Immigration System - Impact on Healthcare Sector
8 Impact on Corporate Strategy
8.1 COVID-19 Impact on the Outcome of Brexit
8.2 COVID-19 Infection Rates Continue to Rise
8.3 COVID-19 Is a Global Problem
8.4 Country Dealing with COVID-19 Pandemic the Best
8.5 Testing for COVID-19
8.6 The UK Leads Top Economies in Vaccines Administered Per Million Population
8.7 The UK Becomes the First Country to Approve a COVID-19 Vaccine
8.8 COVID-19 Vaccine Availability by Country
8.9 Respondents’ Views on the UK Being the First Country to Approve a COVID-19 Vaccine
9 Future Prospects
9.1 Confidence in the UK’s Pharma Sector Post Brexit
9.2 Initiatives that Could Help the UK’s Healthcare Industry to Recover
9.3 Planned Clinical Trials - 2021
9.4 Medicines and Medical Devices Act 2021
9.5 Project Orbis
10 Summary of Key Findings
10.1 Summary of Key Findings
11 Appendix
11.1 Bibliography
11.2 Authors
11.3 Contributors
12 Contact Us
Table of Contents
1 Study Design
1.1 Respondent Mix
1.2 Objectives and Design
1.3 Brexit Timeline
1.4 Respondent Profiles
2 Executive Summary
2.1 Executive Summary
3 UK Pharma Industry and Brexit
3.1 The UK - Real GDP Growth
3.2 The UK Pharma Industry
3.3 Clinical Trial Disruption COVID-19 - A Closer Look
3.4 Change in Brexit Sentiment
3.5 Change in Brexit Sentiment - Respondents’ Perspective
3.6 Brexit and COVID-19 Impact on the UK’s Healthcare Sector
3.7 Emerging Regulatory and Macroeconomic Trends
4 Outcome of Brexit
4.1 The UK-EU Trade and Cooperation Agreement
4.2 Best Outcomes of Brexit
4.3 Best Outcomes of Brexit by Geography
4.4 Best Outcomes of Brexit - Historical Data
4.5 Respondents’ Views on Brexit
5 Impact on Research and Manufacturing
5.1 Brexit’s Impact on Research and Manufacturing
5.2 The UK Pharma Industry Post Brexit
5.3 The UK Pharma Industry Post Brexit - Positives
5.4 The UK Pharma Industry Post Brexit - Negatives
6 Factors to Impact Healthcare
6.1 Factors to Impact the UK’s Healthcare Industry Post Brexit
6.2 Factors to Impact the UK’s Healthcare Industry Post Brexit - Historical Data
6.3 Factors to Impact the UK’s Healthcare Industry Post Brexit by Geography
6.4 The UK-EU Trade and Cooperation Agreement
6.5 Horizon Europe 2020
6.6 The UK-EU Trade and Cooperation Agreement
7 Impact on Corporate Strategy
7.1 Brexit’s Impact on Corporate Strategy
7.2 Brexit’s Impact on Corporate Strategy - 2018 and 2019 Data
7.3 How Has Brexit Most Influenced Corporate Strategy?
7.4 The UK’s Immigration Policy Post Brexit
7.5 UK’s Immigration System - Impact on Healthcare Sector
8 Impact on Corporate Strategy
8.1 COVID-19 Impact on the Outcome of Brexit
8.2 COVID-19 Infection Rates Continue to Rise
8.3 COVID-19 Is a Global Problem
8.4 Country Dealing with COVID-19 Pandemic the Best
8.5 Testing for COVID-19
8.6 The UK Leads Top Economies in Vaccines Administered Per Million Population
8.7 The UK Becomes the First Country to Approve a COVID-19 Vaccine
8.8 COVID-19 Vaccine Availability by Country
8.9 Respondents’ Views on the UK Being the First Country to Approve a COVID-19 Vaccine
9 Future Prospects
9.1 Confidence in the UK’s Pharma Sector Post Brexit
9.2 Initiatives that Could Help the UK’s Healthcare Industry to Recover
9.3 Planned Clinical Trials - 2021
9.4 Medicines and Medical Devices Act 2021
9.5 Project Orbis
10 Summary of Key Findings
10.1 Summary of Key Findings
11 Appendix
11.1 Bibliography
11.2 Authors
11.3 Contributors
12 Contact Us
